Clinical trials: Serplulimab,Gastric Cancer, Adjuvant Therapy
Gastric Cancer
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
- Trial name
- NCT05975749
- Testing
- Serplulimab, Trastuzuma, Chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
HER2-positive Gastric Cancer
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
This is a prospective, single arm, multicenter phase II study to assess the effectiveness of Serplulimab，Trastuzumab and SOX in the adjuvant treatment of HER-2 Positive Gastric/Gastroesophageal Junction Carcinoma (GC/GEJC)
- Trial name
- NCT06439550
- Testing
- Serplulimab, Trastuzumab, Oxaliplatin + Tegafur
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Serplulimab,Gastric Cancer, Adjuvant Therapy
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
To evaluate the efficacy and safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR) .
- Trial name
- NCT05769725
- Testing
- Serplulimab, Docetaxel, S1
- Where
- China
- Volunteers
- 70 people
- Sponsor
- RenJi Hospital